Drugs / Kesuting syrup
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05366231 | May → Sep 2022 | pneumonia | Guizhou Bailing Group Pharmaceutical Co Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kesuting syrup | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05366231 ↗ |
| Route | Oral | “take orally, 20 ml once, three times a day” NCT05366231 ↗ |